2024-514821-45-00招募中2 期
Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)
Medizinische Universitaet Innsbruck1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2024年9月8日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Achievment of major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition
研究概览
简要总结
The rate of major pathological response (MPR) upon neoadjuvant combination therapy with Pembrolizumab and Lenvatinib.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male/female participants ≥18 years of age
- •Histologically or cytologically confirmed primary diagnosis of resectable NSCLC, stages IA2 (minimum primary-tumor diameter 1,5cm) - IIIA (max. single station N2).
- •Measurable disease based on RECIST 1.
- •Male participants must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 120 additional days after the last dose of study treatment and refrain from donating sperm during this period.
- •Female participants are eligible to participate if not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a.) Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b.) A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 120 days after the last dose of study treatment.
- •Written informed consent provided
- •ECOG performance status of 0 to 1
- •Adequate organ function. Specimens must be collected within 14 days prior to the start of study treatment.
排除标准
- •A woman with child-bearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to inclusion (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Patient has received prior radiotherapy for the newly diagnosed NSCLC.
- •Patient has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
- •Patient is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
- •Diagnosis of immunodeficiency and/or patient is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •Known additional malignancy that is progressing.
- •Known history of severe (≥Grade 3) allergic or hypersensitivity reactions to Pembrolizumab or Lenvatinib and/or any of their excipients.
- •Known active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Active infection requiring systemic therapy.
- •Infection with Human Immunodeficiency Virus (HIV).
- •Uncontrolled blood pressure (systolic BP>160mmHg or diastolic BP >95mmHg) despite an optimized regimen of antihypertensive medication.
- •Infection with Hepatitis B and/or Hepatitis C
- •Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Patient has received prior surgery therapy for the newly diagnosed NSCLC.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening visit through 120 days after the last dose of trial treatment.
- •Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, and/or cardiac arrhythmia requiring medical treatment at screening.
- •History of prolonged QT syndrome, or family member with prolonged QT syndrome
- •QTc interval >490 msec when 3 consecutive ECG values are averaged
- •Radiographic evidence of intratumoral cavitations, encasement, or invasion of a major blood vessel. Additionally, the degree of proximity to major blood vessels should be considered cause for exclusion because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib therapy. (In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta).
- •Subjects having > 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is <1 g/24 hours.
- •Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor (eg, CTLA-4, OX 40, CD137).
- •Patient has received prior systemic anti-cancer therapy for the newly diagnosed NSCLC including investigational agents.
结局指标
主要结局
Achievment of major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition
Achievment of major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition
次要结局
- Overall survival at 1, 2, 3 and 5 years
- Radiologic response according to RECIST/iRECIST
- Surgical resection rate
- Disease free survival at 1, 2, 3 and 5 years
- Feasibility and safety of a neoadjuvant/adjuvant treatment
研究者
University Hospital for Internal Medicine V
Scientific
Medizinische Universitaet Innsbruck
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II trial of neoadjuvant combination chemotherapy with gemcitabine and S-1 for locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000001450Faculty of Medicine, Kyoto University35
招募中
1 期
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.MedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864glioblastomaCTIS2023-508278-26-01Z Brussel18
进行中（未招募）
1 期
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancerEUCTR2016-000081-33-DEigartis GmbH42
已完成
2 期
A Phase II Study of Neo-adjuvant Combination Therapy of Trastuzumab and Anastrozole for Hormone Receptor-Positive, HER2-Positive Postmenopausal Breast Cancer(WJOG7412B)Hormone receptor-positive, HER2-positive postmenopausal breast cancerJPRN-UMIN000011023West Japan Oncology Group70
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin